Document Detail

Factors contributing to the utilization of adult mental health services in children and adolescents diagnosed with hyperkinetic disorder.
Jump to Full Text
MedLine Citation:
PMID:  22654608     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVES: To examine whether age of First diagnosis, gender, psychiatric comorbidity, and treatment modalities (pharmacotherapy or psychotherapy) at Child and Adolescent Mental Health Services (CAMHS) moderate the risk of Adult Mental Health Services (AMHS) utilization in patients diagnosed with hyperkinetic disorder at CAMHS.
METHODS: Data were derived from the Madrid Psychiatric Cumulative Register Study. The target population comprised 32,183 patients who had 3 or more visits at CAMHS. Kaplan-Meier curves were used to assess survival data. A series of logistic regression analyses were performed to study the role of age of diagnosis, gender, psychiatric comorbidity, and treatment modalities.
RESULTS: 7.1% of patients presented with hyperkinetic disorder at CAMHS. Compared to preschool children, children and adolescents first diagnosed with hyperkinetic disorder at CAMHS were more likely to use AMHS. Female gender and comorbidity with affective disorders, schizophrenia, schizotypal and delusional disorders increased the risk of use of AMHS. Pharmacological or combined treatment of hyperkinetic disorder diagnosed at CAMHS was associated with increased risk of use at AMHS.
CONCLUSIONS: Older age of first diagnosis, female gender, psychiatric comorbidity, and pharmacological treatment at CAMHS are markers of risk for the transition from CAMHS to AMHS in patients with hyperkinetic disorder diagnosed at CAMHS.
Authors:
Hilario Blasco-Fontecilla; Juan J Carballo; Rebeca Garcia-Nieto; Jorge Lopez-Castroman; Analucia A Alegria; Ignacio Basurte-Villamor; Juncal Sevilla-Vicente; Rocio Navarro-Jimenez; Teresa Legido-Gil; Consuelo Morant-Ginestar; Miguel Angel Jimenez-Arriero; Jeronimo Saiz-Ruiz; Enrique Baca-Garcia
Related Documents :
22395768 - Treatment of dual diagnosis disorders.
24938078 - Current issues in the treatment of specific phobia: recommendations for innovative appl...
21230608 - Asymptotic energy profile of a wave packet in disordered chains.
22275848 - Pharmacotherapy of anxiety disorders: a critical review.
20822268 - Psychometric characteristics and clinical correlates of neo-pi-r fearless dominance and...
9467768 - Affective predictors of dissociation. ii: shame and guilt.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2012-04-30
Journal Detail:
Title:  TheScientificWorldJournal     Volume:  2012     ISSN:  1537-744X     ISO Abbreviation:  ScientificWorldJournal     Publication Date:  2012  
Date Detail:
Created Date:  2012-06-01     Completed Date:  2012-09-27     Revised Date:  2013-07-08    
Medline Journal Info:
Nlm Unique ID:  101131163     Medline TA:  ScientificWorldJournal     Country:  England    
Other Details:
Languages:  eng     Pagination:  451205     Citation Subset:  IM    
Affiliation:
Department of Psychiatry, IIS-Fundación Jiménez Díaz, Autonoma University, 28040 Madrid, Spain.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adolescent
Adolescent Health Services / utilization
Attention Deficit Disorder with Hyperactivity*
Child
Child, Preschool
Female
Humans
Kaplan-Meier Estimate
Male
Mental Disorders
Mental Health Services / utilization*
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Full Text
Journal Information
Journal ID (nlm-ta): ScientificWorldJournal
Journal ID (iso-abbrev): ScientificWorldJournal
Journal ID (publisher-id): TSWJ
ISSN: 1537-744X
Publisher: The Scientific World Journal
Article Information
Download PDF
Copyright © 2012 Hilario Blasco-Fontecilla et al.
open-access:
Received Day: 28 Month: 10 Year: 2011
Accepted Day: 25 Month: 12 Year: 2011
collection publication date: Year: 2012
Electronic publication date: Day: 30 Month: 4 Year: 2012
Volume: 2012E-location ID: 451205
ID: 3361257
PubMed Id: 22654608
DOI: 10.1100/2012/451205

Factors Contributing to the Utilization of Adult Mental Health Services in Children and Adolescents Diagnosed with Hyperkinetic Disorder
Hilario Blasco-Fontecilla1, 2I2
Juan J. Carballo1*
Rebeca Garcia-Nieto1
Jorge Lopez-Castroman1, 2I2
Analucia A. Alegria2, 3I3
Ignacio Basurte-Villamor1
Juncal Sevilla-Vicente1
Rocio Navarro-Jimenez1
Teresa Legido-Gil1
Consuelo Morant-Ginestar4
Miguel Angel Jimenez-Arriero2, 5I5
Jeronimo Saiz-Ruiz2, 3I3
Enrique Baca-Garcia1, 2, 6I2I6
1Department of Psychiatry. IIS-Fundación Jiménez Díaz, Autonoma University, 28040 Madrid, Spain
2Centro de Investigación Biomédica en Red (CIBERSAM), 28007 Madrid, Spain
3Departament of Psiquiatry, Hospital Ramón y Cajal, Alcalá University, 28034 Madrid, Spain
4Department of Mental Health, Madrid Regional Health Council, 28013 Madrid, Spain
5Department of Psychiatry, Hospital Doce de Octubre, Complutense University, 28041 Madrid, Spain
6Department of Psychiatry, New York State Psychiatric Institute, Columbia University, New York, NY 10032, USA
Correspondence: *Juan J. Carballo: juanjocarballo@yahoo.es
[other] Academic Editors: J.-Y. Chen and R. Corcoran

1. Introduction

Research regarding mental health services use is of significant interest given the ongoing efforts to control rising costs of mental health care. Thus, factors related to the transition from Child and Adolescent Mental Health Services (CAMHSs) to Adult Mental Health Services (AMHSs) are a major concern [1]. Longitudinal data assessing continuities of childhood disorders into adulthood [2] may allow to implement early intervention and preventive programmes [3], thus reducing the economic burden of childhood mental disorders progressing into adulthood.

In this context, the study of the continuities of either attention-deficit/hyperactivity disorder (ADHD, DSM-IV), a condition affecting between 4% and 8% of children worldwide [46], or hyperkinetic disorder (HD) (ICD-10), with a 1% worldwide prevalence rate, appears to be relevant [7]. Longitudinal studies followingup children with ADHD have consistently reported high rates of ADHD at follow up [7, 8]. The rate of syndromatic remission of ADHD is around 60% [9, 10]. The majority of subjects, however, continue to struggle with a large number of ADHD symptoms in adulthood [9]. Unfortunately, there is little information about which factors could be associated with an increased risk of utilization of AMHS in patients diagnosed with HD at CAMHS. For instance, it is difficult to determine if age and gender are factors that may increase the risk of utilization of AMHS. Although HD is less frequent in adolescents compared with children [11], continuities of mental disorders are stronger for juvenile diagnosis than for diagnosis made prior to adolescence [12]. Regarding gender, although the clinical profile is similar in boys and girls [13], HD is less prevalent among girls [11, 14, 15]. A priori, severity of symptoms and psychiatric comorbidity are predictors of ADHD persistence [16] and, therefore, should intuitively be associated with an increased use of AMHS. Unfortunately, the bulk of studies have not addressed whether comorbidity moderates treatment outcomes in children with hyperactivity [17]. Finally, pharmacological treatment of HD could intuitively be considered a marker of poor prognosis, as children with HD under pharmacological treatment usually display a more severe clinical profile than children with HD treated with psychotherapy. However, pharmacological treatment could also improve HD, thus preventing the transition from CAMHS to AMHS.

The main purpose of this epidemiological study was to examine whether age of first diagnosis at CAMHS, gender, psychiatric comorbidity diagnosed at CAMHS, and treatment modalities (pharmacotherapy or psychotherapy) at CAMHS moderate the risk of AMHS utilization in patients diagnosed with HD at CAMHS.


2. Methods

Data were derived from the Madrid Psychiatric Cumulative Register (MCR) Study. The MCR study has been described in detail elsewhere [1820]. Briefly, the MCR study is a naturalistic study of diagnostic stability over time. Between January 1986 and December 2007, public mental health centers in the province of Madrid, Spain, recorded all psychiatric visits in a registry. Nonstandardized clinical diagnoses and type of care provided were registered in every follow-up visit by experienced psychiatrists and clinical psychologists. All subjects can be traced because each patient is given a unique, anonymous identifying number, which is the same throughout all contacts with mental health services within the study area.

2.1. Diagnostic Procedure

Lifetime psychiatric diagnoses were made according to the International Classification of Diseases, Tenth Revision (ICD-10, World Health Organization, 1992). The diagnosis of either HD or any other mental health disorder was established after three consecutive visits within the same episode at CAMHS.

2.2. Participants

The target population comprised 32,183 children and adolescents (50.3% females and 49.7% males) who had 3 or more consecutive visits at CAMHS and were 18 years old or older at the time of the present study. We classified patients into four groups according to their first contact with CAMHS and using the US National Library of Medicine and the National Institutes of Health Classification: from birth to 23 months (HD infant group), from 2 to 5 years old (HD preschool children group), from 6 to 12 years old (HD children group), and from 13 to 17 years old (HD adolescent group).

2.3. Predictors of Treatment Use at AMHS

We examined three types of predictors of treatment use at AMHS among individuals diagnosed with HD during childhood and adolescence: sociodemographic characteristics (age of first diagnosis, gender), psychiatric comorbidity, and treatment modalities during followup at CAMHS.

2.4. Data Analyses

First, we used Kaplan-Meier survival curves to compare the likelihood of AMHS use among subjects diagnosed with and without HD at CAMHS. Among individuals with a diagnosis of HD during childhood or adolescence, a series of logistic regression analyses were subsequently performed to examine whether age of first psychiatric diagnosis, gender, and the presence of comorbid psychiatric disorders during followup at CAMHS increased the risk of AMHS use. We calculated odds ratios (ORs) and 95% confidence intervals (CIs) for ease of interpretation. Statistical significance was evaluated at the  .05 level using two-tailed tests. Finally, we used Fisher's Exact Test (FET) to evaluate the role of treatment (pharmacotherapy, psychotherapy, or both) regarding the transition from CAMHS to AMHS. We used SPSS statistical software, edition 17.0 for Mac (2008) for all statistical analyses.


3. Results
3.1. Sample Characteristics

Patients averaged 20 lifetime visits (SD ± 28, range: 4–1036). At the time of first evaluation at CAMHS, 0.1% were infants, 4.4% preschool children, 33.9% children, and 61.7% adolescents. 7.1% of the 32,183 patients were diagnosed with HD before adulthood (0.2% diagnosed as infants, 11.5% as preschool children, 60.0% as children, and 28.2% as adolescents).

3.2. Utilization of AMHS

Subjects diagnosed with HD at CAMHS (n = 2, 274) were less likely to be followedup at AMHS (n = 425, 18.7%) than subjects without a diagnosis of HD at CAMHS (n = 10796, 36.1%) (OR (CI 95%) = 0.43 (0.38–0.48); FET P < 0.001). (see Figure 1).

Children and particularly adolescents first diagnosed with HD at CAMHS were more likely to seek mental health treatment at AMHS than the HD preschool children group (see Table 1). In addition, girls diagnosed with HD at CAMHS used AMHS more frequently than boys diagnosed with HD at CAMHS. Interestingly, subjects diagnosed with HD at CAMHS were less likely to present a comorbid diagnosis of schizophrenia, schizotypal and delusional disorders (F20–29) (OR = 0.585, 95%  CI = 0.458–0.747), or affective disorders (F30–39) (OR = 0.449, 95%  CI = 0.376–0.536) during followup at CAMHS. However, comorbidity of HD with any of the above-mentioned disorders (either F20–29 or F30–39 diagnoses) at CAMHS increased the risk of AMHS utilization (see Table 1).

Finally, children and adolescents diagnosed with HD at CAMHS and treated with pharmacological or combined treatment were significantly more likely to seek mental health treatment at AMHS than children and adolescents with HD diagnosed at CAMHS who were not on pharmacological or combined treatment (OR (95% CI) = 1,75 (1,59–1,92); FET P < 0.001, and OR (95%  CI) = 1,27 (1,16–1,39); FET P < 0.001, resp.). Conversely, psychotherapy was associated with decreased risk of use at AMHS of those children diagnosed with HD at CAMHS (OR (95% CI) = 0,67 (0,61–0,74), FET P < 0.001).


4. Discussion

Our results show that older age of first diagnosis at CAMHS, female gender, comorbidity between HD and other psychiatric diagnoses at CAMHS, and either pharmacological or combined treatment of HD at CAMHS are factors associated with an increased likelihood of followup at AMHS. These results suggest that the previously mentioned factors could be markers of a worse prognosis in subjects diagnosed with HD at CAMHS.

The prevalence of HD in our sample (7.1%) was higher than the prevalence of HD reported in some community samples [21], but similar to the 6.5% lifetime administrative prevalence rate reported by Döpfner et al. [7]. Other authors have also reported similar figures to those reported here. In an epidemiological study carried out in Rochester, the authors found a cumulative incidence of ADHD in the elementary and secondary school children of 7.5% [22]. In the US National Health Interview Survey, the authors reported a prevalence of 6.7% [12]. In addition, few preschool children were diagnosed with HD in the present study. This is not surprising because pre-school children are not usually referred for treatment [11], and this is also in accordance with the literature [9]. In this study, the authors reported a median age for diagnosis of ADHD of 12 years.

Consistent with the available literature, patients diagnosed with HD at CAMHS were less likely to use AMHS than patients without HD at CAMHS. Although it is widely recognized that ADHD and HD persist into adulthood, less than 20% of adults with hyperactivity are diagnosed or treated [23]. This figure is pretty similar to the 18.7% of patients with HD who were followedup in AMHS reported here. Several reasons may explain why subjects diagnosed with HD at CAMHS are less likely to be followedup in AMHS than subjects without HD at CAMHS. First, although symptoms of inattention, impulsivity, and hyperactivity present differently in adulthood, current diagnostic criteria are geared toward symptom identification during childhood [6, 24, 25]. Second, many adults with hyperactivity are seen by mental health practitioners who are not familiar with the adult presentation of the disorder or are reluctant to diagnose ADHD/HD in adults [1]. Third, symptoms of inattention decline at a modest rate while those of hyperactivity and impulsivity remit much more abruptly [6, 26, 27]. Fourth, children with HD may receive different diagnoses (heterotypic continuities) in adulthood. For instance, some cases of adult ADHD are unrecognized and misdiagnosed with conditions such as borderline personality disorder, atypical depression, or cyclothymia [18]. Fifth, some children with HD may have a better outcome than others, being therefore less likely to use AMHS [6]. Sixth, children with ADHD are more likely to have at least one parent exhibiting noteworthy features of ADHD, if not the full diagnosis, than would be expected by chance [28]. Thus, these families might have greater difficulties following through on treatment and hyperactive children might be less likely to seek services upon reaching adulthood. Finally, there might be inconsistencies in the referral process.

Children diagnosed with HD in CAMHS were more likely followedup at AMHS if first diagnosed at an older age and being of female gender. Kim-Cohen et al. [2] reported that continuities between juvenile mental disorders and mental disorders in adulthood are stronger when diagnoses are made after the age of 15. However, other authors have reported that age is not a critical factor for prediction of persistence of HD [16]. The importance of gender is particularly interesting and might point to differential sex-related etiology in this neurodevelopmental disorder. Furthermore, hyperactivity is frequently a “hidden disorder” in girls [29]. It is well established that the prevalence of ADHD and HD is higher in boys [11, 14]. In addition, more boys than girls with hyperactivity receive treatment [30], which may worsen the prognosis of HD in women. This is unfortunate because hyperactive girls do not differ from boys in terms of response to stimulants [31]. Furthermore, concurrent comorbidity and continuity of mental disorders, including ADHD/HD, are more apparent in girls than in boys at least in the transition from childhood to adolescence [32]. In addition, women are overrepresented in adult samples of hyperactive disorders [16] and seek treatment for hyperactivity more frequently than men [9]. Another explanation is that women diagnosed with childhood HD might suffer from a more severe subtype than men in our study. Finally, as suggested by Kessler et al. [16], it is also possible that, as antisocial behavior is more frequent in hyperactive men, more men than women enter jail and are no longer ascertainable in either epidemiologic or clinical studies. Finally, cultural factors might also contribute to gender differences in service seeking.

Patients diagnosed with HD and concurrent comorbidity were also more likely followed up at AMHS. Comorbidity is a distinct feature of ADHD and HD [6]. Subjects diagnosed with ADHD and comorbid conditions during childhood are more likely diagnosed with ADHD (homotypic continuities) and other psychiatric disorders (heterotypic continuities) in the adulthood [33]. Here, it is important to quote that the ICD-10 exclude the diagnosis of HD in the presence of some comorbid diagnoses such as mood or psychotic disorders. This exclusion criterion might explain why we found a low comorbidity rate of affective and psychotic disorders in patients diagnosed with HD at CAMHS. However, the risk of utilization of AMHS was particularly high for those children and adolescents presenting with HD and comorbid affective disorders (F30–39; ICD-10) and schizophrenia, schizotypal and delusional disorders (F20–29; ICD-10) at CAMHS, thus suggesting that children with HD and comorbid mood and psychotic disorders have a poorer outcome than hyperactive children without such a comorbidity, and underscores the need for treatment guidelines to address this issue. Our findings are in accordance with the literature [6]. For instance, children diagnosed with both schizophrenia and hyperactivity have a poorer response to medication and poorer outcome than those diagnosed with schizophrenia alone [10].

Finally, subjects with HD who received pharmacological treatment at CAMHS were more likely to seek treatment at AMHS than those not receiving medication for the HD at CAMHS. Kessler et al. [16] reported that treatment was associated with persistence in the adulthood. These authors suggested that treatment might be interpreted as a “proxy of severity,” and we concur. Children diagnosed with milder forms of HD at CAMHS might be more likely to receive psychological treatment, thus being less likely to seek treatment at AMHS. This might be interpreted either as an example of the effectiveness of psychological treatment in HD, or as a confirmation that psychological treatment is used in less severe HD cases with a better prognosis.

4.1. Strengths and Limitations

The major strength of the present study is that, to our knowledge, this is the largest naturalistic study of transition from CAMHS to AMHS in children and adolescents with HD. Nevertheless, our results should be interpreted in the context of some limitations. First, ICD-10 diagnoses were clinical, nonstandardized diagnoses. However, research and clinical definitions of ADHD and HD rely on reported symptoms and diagnosis is usually made on the basis of clinical impressions [34]. Indeed, rating scales, although useful in documenting hyperactive symptoms as well as the response to treatments, should never be used for diagnosis without careful clinical confirmation [6, 35]. Second, we cannot reject the possibility that our treatment sample was biased due to selection effects (Berkson's bias) [11]. However, our sample size, and the fact that diagnoses were made by several professionals throughout a long period of time, makes this possibility unlikely. Furthermore, it is possible that some patients followed alternative pathways of treatment. Because most Spaniards receive mental health care in public services, this possibility is, however, unlikely [20]. Finally, we used some literature on ADHD to back some of our comments on HD. This was due to the comparatively larger literature on ADHD than on HD. Otherwise, it could have been difficult to put into context some of our findings. Nevertheless, even if DSM-IV ADHDs identify a broader group of hyperactive children than those identified by the ICD-10 HD, there is substantial overlap between both diagnoses [36].


5. Conclusions

An older age of first diagnosis, female gender, comorbidity, and pharmacological treatment at CAMHS might be markers of a worse prognosis in subjects diagnosed with HD at CAMHS. Results from the present study might contribute to a reduction in the economic burden of HD by targeting those children with an increased risk of AMHS utilization.


Acknowledgments

This paper was supported by the National Alliance for Research on Schizophrenia and Affective Disorders (NARSAD), Fondo de Investigacion Sanitaria (FIS) PI060092 and RD06/0011/0016, ETES (PI07/90207), the Conchita Rabago Foundation, the Harriet and Esteban Vicente Foundation, the Spanish Ministry of Health (SAF2010-21849), and Instituto de Salud Carlos III, CIBERSAM (Intramural Project, P91B; Rio Hortega SCO/3410/2004). Dr. Blasco-Fontecilla acknowledges the Spanish Ministry of Health (Rio Hortega CM08/00170), Alicia Koplowitz Foundation, and Conchita Rabago Foundation for funding his postdoctoral stage at CHRU, Montpellier, France.


References
1. Asherson P. Clinical assessment and treatment of attention deficit hyperactivity disorder in adultsExpert Review of NeurotherapeuticsYear: 20055452553916026236
2. Kim-Cohen J,Caspi A,Moffitt TE,Harrington H,Milne BJ,Poulton R. Prior juvenile diagnoses in adults with mental disorder: developmental follow-back of a prospective-longitudinal cohortArchives of General PsychiatryYear: 200360770971712860775
3. Reef J,Diamantopoulou S,Van Meurs I,Verhulst F,Van Der Ende J. Child to adult continuities of psychopathology: a 24-year follow-upActa Psychiatrica ScandinavicaYear: 2009120323023819522882
4. Dulcan M,Dunne JE,Ayres W,et al. Practice parameters for the assessment and treatment of children, adolescents, and adults with attention-deficit/hyperactivity disorderJournal of the American Academy of Child and Adolescent PsychiatryYear: 1997361085S121S9334567
5. Polanczyk G,Rohde LA. Epidemiology of attention-deficit/hyperactivity disorder across the lifespanCurrent Opinion in PsychiatryYear: 200720438639217551354
6. Spencer TJ,Biederman J,Mick E. Attention-deficit/hyperactivity disorder: diagnosis, lifespan, comorbidities, and neurobiologyAmbulatory PediatricsYear: 200771738117261486
7. Döpfner M,Breuer D,Wille N,Erhart M,Ravens-Sieberer U. How often do children meet ICD-10/DSM-IV criteria of attention deficit-/hyperactivity disorder and hyperkinetic disorder? Parent-based prevalence rates in a national sample - Results of the BELLA studyEuropean Child and Adolescent PsychiatryYear: 2008171597019132305
8. Larsson H,Lichtenstein P,Larsson JO. Genetic contributions to the development of ADHD subtypes from childhood to adolescenceJournal of the American Academy of Child and Adolescent PsychiatryYear: 200645897398116865040
9. Biederman J,Faraone SV,Spencer TJ,Mick E,Monuteaux MC,Aleardi M. Functional impairments in adults with self-reports of diagnosed ADHD: a controlled study of 1001 adults in the communityJournal of Clinical PsychiatryYear: 200667452454016669717
10. Elman I,Sigler M,Kronenberg J,et al. Characteristics of patients with schizophrenia successive to childhood attention deficit hyperactivity disorder (ADHD)Israel Journal of Psychiatry and Related SciencesYear: 19983542802869988985
11. Bauermeister JJ,Shrout PE,Ramírez R,et al. ADHD correlates, comorbidity, and impairment in community and treated samples of children and adolescentsJournal of Abnormal Child PsychologyYear: 200735688389817505876
12. Woodruff TJ,Axelrad DA,Kyle AD,Nweke O,Miller GG,Hurley BJ. Trends in environmentally related childhood illnessesPediatricsYear: 200411341133114015060210
13. Smalley SL,McGough JJ,Moilanen IK,et al. Prevalence and psychiatric comorbidity of attention-deficit/hyperactivity disorder in an adolescent Finnish populationJournal of the American Academy of Child and Adolescent PsychiatryYear: 200746121575158318030079
14. Pastura G,Mattos P,Araújo APDQC. Prevalence of attention deficit hyperactivity disorder and its comorbidities in a sample of school-aged childrenArquivos de Neuro-PsiquiatriaYear: 20076541078108318094880
15. Tossell JW,Greenstein DK,Davidson AL,et al. Stimulant drug treatment in childhood-onset schizophrenia with comorbid ADHD: an open-label case seriesJournal of Child and Adolescent PsychopharmacologyYear: 200414344845415650502
16. Kessler RC,Adler LA,Barkley R,et al. Patterns and predictors of attention-deficit/hyperactivity disorder persistence into adulthood: results from the national comorbidity survey replicationBiological PsychiatryYear: 200557111442145115950019
17. Ollendick TH,Jarrett MA,Grills-Taquechel AE,Hovey LD,Wolff JC. Comorbidity as a predictor and moderator of treatment outcome in youth with anxiety, affective, attention deficit/hyperactivity disorder, and oppositional/conduct disordersClinical Psychology ReviewYear: 20082881447147118973971
18. Baca-Garcia E,Perez-Rodriguez MM,Basurte-Villamor I,et al. Diagnostic stability of psychiatric disorders in clinical practiceBritish Journal of PsychiatryYear: 200719021021617329740
19. Carballo JJ,Baca-Garcia E,Blanco C,et al. Stability of childhood anxiety disorder diagnoses: a follow-up naturalistic study in psychiatric careEuropean Child and Adolescent PsychiatryYear: 201019439540319826859
20. Carballo JJ,Muñoz-Lorenzo L,Blasco-Fontecilla H,et al. Continuity of depressive disorders from childhood and adolescence to adulthood: a naturalistic study in community mental health centers Primary Care Companion, 13, 2011.
21. Polanczyk G,De Lima MS,Horta BL,Biederman J,Rohde LA. The worldwide prevalence of ADHD: a systematic review and metaregression analysisAmerican Journal of PsychiatryYear: 2007164694294817541055
22. Barbaresi WJ,Katusic SK,Colligan RC,et al. How common is attention-deficit/hyperactivity disorder? Incidence in a population-based birth cohort in Rochester, MinnArchives of Pediatrics and Adolescent MedicineYear: 2002156321722411876664
23. Newcorn JH,Weiss M,Stein MA. The complexity of ADHD: diagnosis and treatment of the adult patient with comorbiditiesPrimary PsychiatryYear: 2007148115
24. McGough JJ,Barkley RA. Diagnostic controversies in adult attention deficit hyperactivity disorderAmerican Journal of PsychiatryYear: 2004161111948195615514392
25. Adler LA. From childhood into adulthood: the changing face of ADHDCNS spectrumsYear: 200712126918396510
26. Biederman J,Mick E,Faraone SV. Age-dependent decline of symptoms of attention deficit hyperactivity disorder: impact of remission definition and symptom typeAmerican Journal of PsychiatryYear: 2000157581681810784477
27. Hart EL,Lahey BB,Loeber R,Applegate B,Frick PJ. Developmental change in attention-deficit hyperactivity disorder in boys: a four-year longitudinal studyJournal of Abnormal Child PsychologyYear: 19952367297498609310
28. Thapar A,Holmes J,Poulton K,Harrington R. Genetic basis of attention deficit and hyperactivityBritish Journal of PsychiatryYear: 199917410511110211163
29. Quinn PO. Treating adolescent girls and women with ADHD: gender-specific issuesJournal of Clinical PsychologyYear: 200561557958715723425
30. Derks EM,Hudziak JJ,Boomsma DI. Why more boys than girls with ADHD receive treatment: a study of Dutch twinsTwin Research and Human GeneticsYear: 200710576577017903118
31. Sharp WS,Walter JM,Marsh WL,Ritchie GF,Hamburger SD,Castellanos FX. ADHD in girls: clinical comparability of a research sampleJournal of the American Academy of Child and Adolescent PsychiatryYear: 199938140479893415
32. Costello EJ,Mustillo S,Erkanli A,Keeler G,Angold A. Prevalence and development of psychiatric disorders in childhood and adolescenceArchives of General PsychiatryYear: 200360883784412912767
33. Reimherr FW. Comorbidity and diagnosis of ADHDCNS spectrumsYear: 200611107917712917
34. Barkley R. Attention-Deficit/Hyperactivity Disorder: A Handbook for Diagnosis and TreatmentYear: 1998New York, NY, USAGuildford Press
35. Wolraich ML,Wibbelsman CJ,Brown TE,et al. Attention-deficit/hyperactivity disorder among adolescents: a review of the diagnosis, treatment, and clinical implicationsPediatricsYear: 200511561734174615930238
36. Tripp G,Luk SL,Schaughency EA,Singh R. DSM-IV and ICD-10: a comparison of the correlates of ADHD and hyperkinetic disorderJournal of the American Academy of Child and Adolescent PsychiatryYear: 19993821561649951214

Article Categories:
  • Research Article


Previous Document:  Imaging modalities for the noninvasive assessment of fibrosis in Crohn's disease.
Next Document:  The effects of addition of mononucleotides on Sma nuc endonuclease activity.